Acción 6497 ASLAN PHARMACEUTICALS LIMITED
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate
Instrumento Inactivo

Otros idiomas ASLAN Pharmaceuticals Limited Taipei Exchange

Acciones

6497

KYG054241099

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Asian Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading
Asian Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading
Asian Equities Traded in the US as American Depositary Receipts Begin Week Higher
ASLAN Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended March 31, 2024
ASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
Asian Equities Traded in the US as American Depositary Receipts Trend Slightly Lower in Wednesday Trading
Asian Equities Traded in the US as American Depositary Receipts Drop Sharply in Tuesday Trading
ASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Event
Aslan Pharmaceuticals to Present Additional Data from Interim Analysis of Trek-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Event
Tech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Slightly Higher in Monday Trading
Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Friday Trading, End Week Over 2% Higher
Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Thursday Trading
ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics
ASLAN Pharmaceuticals Announces Expansion of its Collaboration with Zenyaku Kogyo Co., Ltd. to Investigate Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics
Asian Equities Traded in the US as American Depositary Receipts Nudge Lower in Wednesday Trading
ASLAN Pharmaceuticals to Host KOL Panel Discussion on Treatment Options for Atopic Dermatitis Patients With an Inadequate Response to Dupilumab
Asian Equities Traded in the US as American Depositary Receipts Open Week on Flat Note in Monday Trading
Asian Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.5%
Tech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Lower in Thursday Trading
ASLAN Pharmaceuticals Announces Late Breaking Abstract on Eblasakimab in COPD Accepted for Presentation at the American Thoracic Society International Conference
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción ASLN
  4. Acción 6497
  5. Noticias ASLAN Pharmaceuticals Limited
  6. Otros idiomas